ClinicalTrials.gg
RecruitingNCT07758842LIFE-MetS-EDUpdated Aug 14, 2026

Lifestyle Modification for Erectile Dysfunction in Men With Metabolic Syndrome

An interventional study of Structured Lifestyle Modification Program in Erectile Dysfunction and Metabolic Syndrome, sponsored by Al-Azhar University. Recruiting at 2 sites in Egypt. Open to male participants aged 30 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-08-14.

Sponsored by Al-Azhar University · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Started Aug 2026; still recruiting 2 months later.
Phase
Not applicable
Study type
Interventional
Enrollment
55
Allocation
Not applicable
Ages
30 Years to 65 Years
Sex
Male
01

Study summary

Metabolic syndrome is associated with erectile dysfunction through obesity, insulin resistance, abnormal blood lipids, high blood pressure, and impaired blood-vessel function. This study will evaluate whether a structured six-month lifestyle-modification program can improve penile blood flow and erectile function in men with metabolic syndrome-associated erectile dysfunction.

Eligible participants will receive dietary counseling, exercise guidance, weight-management advice, smoking-cessation counseling when applicable, sleep and sedentary-behavior advice, and repeated behavioral reinforcement. Erectile function, penile blood-flow measurements obtained by penile duplex Doppler ultrasonography, body measurements, and selected metabolic laboratory parameters will be assessed before the program and after six months.

Read the detailed description

This prospective single-arm interventional study will evaluate the effect of a structured six-month lifestyle-modification program on penile hemodynamic parameters and erectile function in adult men with metabolic syndrome-associated erectile dysfunction.

Participants will undergo baseline assessment including demographic and clinical data collection, anthropometric measurements, blood-pressure assessment, erectile-function evaluation using the International Index of Erectile Function-5, selected laboratory investigations, and penile duplex Doppler ultrasonography after intracavernosal administration of a vasoactive agent according to the local institutional protocol.

The lifestyle program will include individualized dietary counseling, recommendations for regular moderate-intensity aerobic physical activity, weight-reduction advice, smoking-cessation counseling for smokers, sleep-hygiene counseling, reduction of sedentary behavior, and behavioral reinforcement during follow-up visits. Participants will be followed monthly for adherence reinforcement and will undergo repeat clinical, laboratory, erectile-function, and penile hemodynamic assessments at six months.

The principal hypothesis is that structured lifestyle modification will improve penile hemodynamic parameters, particularly peak systolic velocity, and will improve erectile-function scores in men with metabolic syndrome-associated erectile dysfunction.

02

Conditions studied

  • Erectile Dysfunction
  • Metabolic Syndrome
03

In context

Erectile Dysfunction

701 studies on the registry are indexed under Erectile Dysfunction; 125 are open to participants now.

This study's planned enrollment of 55 is below the median of 70 across 551 interventional studies indexed under Erectile Dysfunction.

Browse Erectile Dysfunction studies →

Lead sponsor

Al-Azhar University is the lead sponsor of 531 studies on the registry; 172 are open to participants now.

Of its 5 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
30 Years to 65 Years
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Men aged 30-65 years.
  • Erectile dysfunction present for at least six months.
  • International Index of Erectile Function-5 score of 21 or less.
  • Metabolic syndrome diagnosed according to the International Diabetes Federation criteria.
  • Sexually active participants in a stable sexual relationship.
  • Willingness and ability to participate in the six-month lifestyle-modification program.
  • Ability to provide written .

Exclusion criteria

Exclusion Criteria:

  • Erectile dysfunction primarily attributable to neurogenic, psychogenic, hormonal, or postsurgical causes.
  • Severe hypogonadism requiring immediate testosterone-replacement therapy.
  • Use of phosphodiesterase type 5 inhibitors, intracavernosal injections, vacuum erection devices, or other erectile-dysfunction treatment that cannot be discontinued before baseline assessment.
  • Significant penile anatomical abnormality that may interfere with penile duplex Doppler assessment, including Peyronie disease.
  • Previous pelvic surgery or pelvic radiotherapy likely to affect erectile function.
  • Severe or unstable cardiovascular disease that precludes sexual activity or participation in exercise-based lifestyle modification.
  • Uncontrolled diabetes mellitus, defined in the protocol as greater than 10%.
  • Uncontrolled hypertension despite medical therapy.
  • Severe renal or hepatic impairment.
  • Active or of less than one year.
  • Major psychiatric illness, cognitive impairment, or inability to comply with study procedures or follow-up.
  • Inability or refusal to provide written .
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
55 participants (estimated)

Study arms

  • Experimental
    Structured Lifestyle Modification

    Participants will receive a structured six-month lifestyle-modification program consisting of dietary counseling, moderate-intensity physical-activity advice, weight-management counseling, smoking-cessation counseling when applicable, sleep-hygiene advice, reduction of sedentary behavior, and monthly behavioral reinforcement.

    Behavioral: Structured Lifestyle Modification Program

Interventions

  • BehavioralStructured Lifestyle Modification Program

    Participants will receive an initial standardized counseling session followed by written lifestyle instructions and repeated monthly reinforcement. The program will target improved diet quality, reduced caloric intake, increased moderate-intensity aerobic activity, weight reduction according to baseline body mass index and waist circumference, smoking cessation when applicable, improved sleep hygiene, and reduced sedentary behavior. Adherence will be assessed using participant self-report and follow-up review over six months.

06

What researchers measure

Primary outcomes

  1. Change in penile peak systolic velocity from baseline to six months

    Change in peak systolic velocity measured in centimeters per second by penile duplex Doppler ultrasonography after intracavernosal vasoactive-agent administration, comparing the baseline value with the six-month post-intervention value.

    Time frame: Baseline and six months after initiation of the lifestyle-modification program.

Secondary outcomes

  1. Change in International Index of Erectile Function-5 / Sexual Health Inventory

    Change in total score from baseline to 6 months. Score range 5-25; higher scores indicate better erectile function.

    Time frame: Baseline and six months

  2. Change in end-diastolic velocity

    Change in the total score of the International Index of Erectile Function-5 (IIEF-5) questionnaire from baseline to 6 months. The IIEF-5 total score ranges from 5 to 25, with higher scores indicating better erectile function and lower scores indicating greater erectile dysfunction.

    Time frame: Baseline and six months.

  3. Change in resistive index

    Change in penile resistive index calculated from penile duplex Doppler measurements.

    Time frame: Baseline and six months.

  4. Change in body weight

    Change in body weight measured in kilograms.

    Time frame: Baseline and six months.

  5. Change in waist circumference

    Change in waist circumference measured in centimeters using a standardized measurement method.

    Time frame: Baseline and six months.

07

Study locations

2 of 2 sites recruiting
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Aug 14, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07758842
Responsible party
Abul-fotouh Ahmed (Professor of Urology, Al-Azhar University) — Principal investigator
First posted
Aug 11, 2026
Start date
Aug 13, 2026
Primary completion
Jul 24, 2027 (estimated)
Completion
Nov 24, 2027 (estimated)
Last update
Aug 14, 2026

Study contacts

Abul-fotouh Ahmed, MD
Contact
abulfotouhahmed7070@gmail.com
00201001066756
Abul-fotouh Ahmed, MD
principal investigator · Al-Azhar University

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion